All In Biotech

Drug Trial Radar · NCT07111520

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

880

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Nov 2028

Study completion Jun 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
MediLink Therapeutics (Suzhou) Co., Ltd.
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available). The main goals of this study are: 1. To find the best dose levels (DLs) for the combination of BNT326 and pumitamig. 2. To look at how well participants with advanced NSCLC tolerate the combination therapy (for example, which side effects participants experience and how severe they are). 3. To look at how well the combination therapy works to shrink the tumor in participants with advanced NSCLC.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • BNT326Drug

    intravenous (IV) infusion

  • PumitamigDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participantTime frame: 21 days starting on Day 1 of Cycle 1
  2. Part 1 and Part 2a - Occurrence of treatment emergent adverse events (TEAEs), treatment-related adverse events (TRAE), treatment emergent serious adverse events (TESAE), treatment-related serious adverse events (TRSAE)Time frame: from the first dose of investigational medicinal product (IMP) up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
  3. Part 1 and Part 2a - Occurrence of dose interruption, reduction, and discontinuation due to TEAEsTime frame: from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
  4. Part 2a and Part 2b - Objective response rate (ORR)Time frame: from the time of initiation of the first dose of IMP to approximately 36 months

Locations

87 sites in 10 countries. Site status is shown where the registry gives one.

  • UCLA Hematology Oncology - Main Site

    Los Angeles, California · Recruiting

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Georgetown University - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Moffit Cancer Center

    Tampa, Florida · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center

    Cleveland, Ohio · Recruiting

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Cancer Research SA

    Adelaide, Australia · Recruiting

  • St George Private Hospital

    Kogarah, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, Australia · Recruiting

  • Mater

    South Brisbane, Australia · Recruiting

  • John Flynn Private Hospital

    Tugun, Australia · Recruiting

  • Westmead Hospital

    Westmead, Australia · Recruiting

  • Affiliated Hospital of Hebei University

    Baoding, China · Recruiting

  • Beijing GoBroad Hospital

    Beijing, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, China · Recruiting

  • The First Affiliated Hospital School of Clinical Medicine of Guangdong Pharmaceutical University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China · Recruiting

  • Anhui Chest Hospital

    Hefei, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, China · Recruiting

  • Jinan Central Hospital

    Jinan, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, China · Recruiting

  • Shanghai East Hospital

    Shanghai, China · Recruiting

  • Shanghai GoBroad Cancer Hospital

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, China · Recruiting

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.